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Background: Mesenchymal stromal cells (MSC) can be obtained from potentially any tissue from the human body,
but cells purified from different sources are undoubtedly different, and for each medical application, the MSC with
the best regenerative potential should be chosen.
Results: Bone marrow-derived mesenchymal stromal cells (BM-MSC), adipose tissue-derived mesenchymal stromal
cells (AT-MSC) and Wharton’s Jelly-derived mesenchymal stromal cells (WJ-MSC) were isolated from human tissues
and were cultured under differentiation media supplemented with fetal bovine serum. We quantified the expression
of stem cell and adipocyte genetic markers using quantitative real time PCR, as well as the secretion of cytokines,
extracellular matrix components and growth factors using Luminex and ELISA. All three MSC differentiated into adi-
pogenic cells. AT-MSC showed the highest shift in ADIPOQ, CEBPA and PPARG mRNA expression. BM-MSC kept high
expression levels of stem-cell markers SOX2 and POU5F1. WJ-MSC showed the lowest increase in mRNA expression
when cells were induced to differentiate into adipocytes. Regarding protein secretion, adipocyte-like cells generated
from WJ-MSC secreted the highest chemokine levels. AT-MSC-derived adipocyte-like cells secreted the lowest cyto-
kine amounts and the highest quantity of collagen types I and III. Adipocyte-like cells obtained from BM-MSC se-
creted high amounts of most angiogenic factors, growth factors TGF-β1 and TGF-β2, collagens type II and IV,
heparan sulfate, laminin and aggrecan.
Conclusion: Mesenchymal stromal cells purified from different tissues have a different behavior when induced to
differentiate into adipocyte-like cells.
Keywords: Human mesenchymal stromal cells, Adipogenesis, qPCR, Protein quantificationBackground
Adipose tissue has gained intense interest in the last de-
cades. Early in the 19 s, adipose tissue was considered
an agglomeration of fat-storing adipocytes surrounded
by connective tissue. Only in 1948, Shapiro and
Wertheimer suggested that adipose tissue was metabol-
ically active [1]. Since then, several studies have im-
proved our knowledge of adipose tissue metabolic,
endocrine and immunologic functions. Fully differenti-
ated adipocytes were first isolated using collagenase and* Correspondence: pramable@gmail.com
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unless otherwise stated.flotation in 1964 by Rodbell [2]. Early in the 1990s, the
first evidence of adipose tissue secretory function was
reported [3]. Adipocytes secrete a wide variety of pro-
teins, including adipokines, a family of proteins exclu-
sively secreted by adipocytes [4]. The first adipokine
described in 1994 was leptin, which confirmed that fat
tissue has an important endocrine function [3].
In 2001, Zuk and colleagues described the procedure
to process lipoaspirates [5]. The same group published
subsequently biochemical and molecular analysis of the
adipose tissue-derived stem cells, confirming their differ-
entiation capacity into different mesodermal cell types
and the expression of specific genes [6]. The possibility
of stem cell isolation from the easily accessible andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and regenerative medicine field.
Before researchers completely understood adipose tis-
sue biology, fat was already used in cosmetic, plastic,
and reconstructive surgeries. In 1893, Neuber performed
the first clinical fat transplantation, using small pieces of
autologous material for filling depressed scars [7]. Prob-
lems related to necrosis, cyst formation and reabsorption
were usual, due to low revascularization, especially when
large fat pieces were transplanted.
Autologous fat transplantation has several advantages:
it results in a satisfactory tissue repair, avoids large inci-
sion scars, causes no immune host responses, and avoids
use of prosthesis. Its major disadvantage is the appar-
ently unpredictable survival of the transplanted fat, since
variable resorption rates have been reported (10% to
90%; [8]). In order to obtain the desired final volume of
implant, multiple interventions may be required [9]. Ma-
ture adipocytes are fragile cells, and a large part may suf-
fer extensive lesions with a loss of membrane integrity
and release of fat. Sydney Coleman developed in 1986 an
improved method for fat transplantation that minimizes
the stress during tissue collection, by recommending
transplantation of small fat tissue fragments in multiple
steps, in order to facilitate revascularization and, there-
fore, tissue survival. This tissue processing, called Cole-
man’s method, resulted in reduced graft resorption [10].
The discovery of stem cells in adipose tissue by Zuk
and colleagues in 2001 complemented the understanding
of the durability of fat transfer [5]. Matsumoto and co-
workers developed in the year 2006 a new technique to
reduce tissue resorption, using the “cell-assisted lipo-
transfer” [11]. The technique consisted in separating a
part of the aspirated fat in a stromal vascular fraction
enriched in MSC. The lipotransfer containing these cells
allowed a higher survival and vascularization of the graft
in pre-clinical and clinical trials [12]. Further studies
have proposed alternative procedures to manipulate
lipoaspirates, and overall recommendations for handling
of samples and for characterization of transferred cells
[12,13].
The MSC content in primary cell suspensions col-
lected from lipoaspirates is however low. Immunophe-
notyping of cells in the stromal fraction indicates
presence of blood-vessel components and associated ele-
ments, as well as pre-adipocytes and MSC. The latter
two are characterized as CD45neg, CD34pos and/or
CD105pos, and their content in the stromal fraction was
reported to be below 5% [14]. Rigotti and coworkers re-
ported in the year 2007 that the content of MSC in the
adipose tissue stromal fraction was in order of 1%, but
importantly, the level of clonogenic colony-forming
units that possibly better reflects the quantity of cells
able to participate in long-term tissue regeneration wastenfold lower [15]. In contrast, when selected by plastic
adhesion (after in vitro tissue digestion) and expanded
in vitro, MSC are selected and can represent 70-90% of
the harvested cells. The use of these cells offers new
cues in regenerative procedures using much higher
levels of MSC in the “cell-assisted lipotransfers”.
The MSC used in this procedure can be autologous, re-
quiring a first harvest of fat tissue to establish cultures,
and a second one to provide the tissue for the graft. When
the donor adipose tissue is limited, alternative sources of
MSC may be used, associated with autologous fat graft, in
order to grant a long-term restoration of fat tissue under
controlled conditions, maintaining the volume and the
implant’s form. Among others, this may be the case of fa-
cial fat restoration in lipodystrophies or in chronic HIV
infection [16-18]. We hypothesized that MSC from differ-
ent origins other than adipose tissue can be used in assist-
ing fat transplantation, especially if they show a high
adipogenic differentiation potential. MSC obtained from
the Wharton’s Jelly of the umbilical cord, a convenient
source of cells with high proliferation capacity, may be
proposed for allogeneic transplantation. Therefore, we
characterized MSC obtained from different sources
(adipose tissue, Wharton’s Jelly and bone marrow) regard-
ing their ability to differentiate into adipocytes.
Characterization of MSC and their ability to differenti-
ate into adipocytes may be relevant in many other fields
of regenerative medicine. Novel proposals for tendon
and muscle regeneration deal with the use of MSC for
repair of such lesions of shoulder, which are particularly
sensitive to the fatty degeneration of muscles [19]. This
is generally an irreversible process, in which adipocytes
invade and replace the muscle tissue. The origin of these
adipocytes is a differentiation from resident MSC, which
in the absence of mechanical stimulation by muscle con-
traction suffer a decrease of Wnt signaling, leading to
transcription of adipogenic factors such as PPARγ, C/
EBPα and leptin [20]. Knowledge of which MSC already
express, or easily activate expression of adipogenic fac-
tors, and readily differentiate into adipocytes, may be
relevant for the choice of MSC to be used in such a
therapy.
In the present study, we compared adipogenic differ-
entiation in vitro of MSC derived from bone marrow,
adipose tissue and Wharton’s Jelly. Our main goal is to
determine which source of MSC is more appropriate for
allogeneic transplantation, so they can be use together
with adipose tissue for long-lasting effects after fat trans-
plantation. We quantified the gene expression of key
pluripotent and differentiation markers, and the secre-
tion of different proteins, and we compared these results
with those recently obtained by our group regarding
protein secretion of undifferentiated BM-MSC, AT-MSC
and WJ-MSC.
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MSC obtained from human bone marrow, adipose tissue
and Wharton’s Jelly identity was confirmed: they ad-
hered to the plastic surfaces of cell culture flasks with a
fibroblast–like morphology, expressed the cell surface
markers CD73, CD90 and CD105 and negative for
hematopoietic markers (HLA-DR, CD45, CD14 and
CD34) [15]. MSC also differentiated into all three meso-
dermal lineages: adipocytes, osteoblasts and chondro-
blasts (results shown in 24).
All MSC cultured in DMEM supplemented with FBS
and with the compounds recommended for adipocyte
induction differentiated into adipocyte-like cells. Differ-
entiation controls maintained in the standard medium
were run in parallel for all conditions, and they were all
negative, not presenting any visible lipid accumulation
(data not shown).
Gene expression during differentiation into adipocyte-like
cells
Gene expression of pluripotent (SOX2, POU5F1 and
TERT) and adipogenic (PPARG, ADIPOQ and CEPBA)
markers were studied, evaluating cell differentiation ef-
fects on gene expression. Appropriate reference genes
were RPL13A for WJ-MSC and AT-MSC, and HPRT1
for BM-MSC [21].
TERT expression was not detected in any sample. Pub-
lished data are contradictory regarding TERT expression:
some authors described TERT mRNA as a pluripotent
marker in BM-MSC [25] but many others detected nei-
ther TERT mRNA [26] nor TERT activity [27,28] in
MSC primary cultures.
Data on mRNA expression during adipogenic differen-
tiation are shown in Table 1. A statistical analysis was
performed comparing the expression of one gene for all
cells and time points evaluated. For all the genes, AT-
MSC at day 21 expressed statistically significant higherTable 1 Relative gene expression (expressed in mean ± stand
marrow- (BM-) and Wharton’s Jelly-mesenchymal stromal cell
mented with 10% fetal bovine serum
BM-MSC AT-MSC
d10 d21 d10
PPARG 14.9 ± 2.5 a 32.3 ± 3.0 a 21.0 ± 6.4 a
ADIPOQ 4,126.8 ± 3,370.2 a 3,994.2 ± 1,292.7 a 3,378.4 ± 2,
CEBPA 102.6 ± 14.6 a 89.7 ± 33.1 a 206.6 ± 53.9
SOX2 ** 2.5 ± 1.4 a 7.1 ± 0.8 a
POU5F1 0.7 ± 0.3 a 0.6 ± 0.1 a 4.0 ± 1.0 a
ADIPOQ: adiponectin; AT-MSC: adipose tissue-derived MSC; BM-MSC: bone marrow-
day 21; MSC: mesenchymal stromal cells; POU5F1: POU domain, class 5, transcriptio
SRY (Sex Determining Region Y)-Box 2; WJ-MSC: Wharton’s Jelly-derived MSC; *not d
or d21).
Negative values mean downregulation on mRNA expression when compared to non-i
was assessed by one-way non-parametric ANOVA followed by Bonferroni post-hoc tes
row, a same letter means that both conditions are not significantly different; differentamounts of the corresponding mRNA. Regarding pluri-
potent markers, only POU5F1 was downregulated in
BM-MSC cultures.
Regarding adipogenic markers, ADIPOQ was detected
only at day 0 in WJ-MSC, but it showed the highest in-
crease in AT-(day 21) and BM-MSC (day 10). Highest
upregulation of adipogenic markers in BM-MSC and
AT-MSC correlated with highest lipid accumulation in
differentiation assays and with a lower expression levels
of WJ-MSC.
Protein secretion by adipocyte-like cells
Results from cell culture supernatant quantification of
secreted chemokines, pro- and anti-inflammatory cyto-
kines, angiogenic and growth factors, extracellular
matrix components and matrix metalloproteinases are
shown in Table 2. In order to make results comparable,
supernatant concentration was expressed in pg secreted
per million cells and per day, since MSC from different
sources proliferated in significantly different rates when
differentiated into the adipogenic phenotype. Final cell
concentration was 26,000.90 cells/mL for BM-MSC,
123,333.4 cells/mL for AT-MSC and 296,875.0 cells/mL
for WJ-MSC.
Only IP-10 and MCP-1 were detected in supernatants
of cells induced to differentiate into adipocytes. IP-10 se-
cretion was higher for WJ-MSC, and MCP-1 was higher
for BM-MSC. AT-MSC secreted the lowest concentra-
tion of both chemokines.
Pro-inflammatory cytokines GM-CSF, IL-1β, TNF-α,
IFN-γ, IL-2, IL-2R, IL-15 and IL-17 were not detected in
any of the supernatants of differentiated cells. Only IL-6,
IL-7, IL-8 and IL-12 were detected in all supernatants.
Again, AT-MSC secreted the lowest concentration of all
4 detected cytokines. BM-MSC secreted higher amounts
of IL-7 and IL-12, with concentration rates of 102.4 ±
57.8 and 41.5 ± 7.6 pg/106 cells/day, respectively. On theard deviation) for human adipose tissue- (AT-), bone
s (WJ-MSC) when grown in low glucose media supple-
WJ-MSC
d21 d10 d21
58.3 ± 13.6 b 15.2 ± 8.9 a 29.1 ± 3.2 a
243.0 a 423,626.8 ± 147,352.8 b * *
a 1,271.3 ± 245.3 b 12.1 ± 6.6 a 17.3 ± 4.3 a
4,800.8 ± 387.7 b 5.8 ± 3.0 a 3.0 ± 1.1 a
142.5 ± 0.2 b 3.9 ± 2.2 a 0.3 ± 0.1 a
derived MSC; CEPBA: CCAAT/enhancer-binding protein alpha; d10: day 10; d21:
n factor 1; PPARG: peroxisome proliferator-activated receptor gamma; SOX2:
etected in initial sample (d0); **not detected in that particular sample (d10
nduced cultured cells, and positive values, upregulation. Statistical significance
t to compare all pairs of data for a determined gene (α = 0.05, n = 3). In a same
letters (superscript letters a and b) indicate statistically different values.
Table 2 Protein secretion (expressed as mean ± standard deviation) of adipose tissue- (AT-), bone marrow- (BM-) and




IP-10 0.8 ± 0.3 a nd 3.5 ± 0.4 a
MCP-1 727.5 ± 86.5 a 336.2 ± 42.2 b 551.5 ± 51.6 a,b
Pro-inflammatory cytokines (pg/106 cells/day)
IL-6 46.6 ± 2.8 a 31.2 ± 4.3 a 146.0 ± 31.6 b
IL-7 102.4 ± 57.8 a 0.13 ± 0.19 a 0.07 ± 0.10 a
IL-8 628.3 ± 8.0 a 63.7 ± 2.7 a 4,466.3 ± 634.6 b
IL-12 41.5 ± 7.6 a 1.6 ± 2.3 a nd
Anti-inflammatory cytokines (pg/106 cells/day)
IL-1ra 30.00 ± 0.01 a nd 205.3 ± 28.7 a
Angiogenic factors (pg/106 cells/day)
Angiogenin 3,054.7 ± 74.2 a 995.3 ± 34.9 b 517.9 ± 5.3 c
Thrombospondin-2 79,967.7 ± 149.8 a 35,564.0 ± 1,644.6 b 155,582.9 ± 6,467.8 c
PLGF 102.4 ± 2.1 a 12.5 ± 1.0 a nd
aFGF 65.7 ± 12.4 a 6.9 ± 6.5 b 14.0 ± 2.6 b
VEGF-D 24.80 ± 0.01 nd nd
Endostatin 1,322.3 ± 24.7 a 1,270.4 ± 21.6 a 2,343.3 ± 68.7 b
Angiopoietin-1 129,196.1 ± 8,604.8 b 12,502.3 ± 405.8 a 17,114.5 ± 51.9 a
VEGF 3,431.8 ± 180.9 b 392.4 ± 24.4 a 3.4 ± 0.8 a
Growth factors (pg/106 cells/day)
TGF-β1 4,051.7 ± 0.0 a 1,844.7 ± 205.9 b 1,622.6 ± 51.1 b
TGF-β2 178.1 ± 1.1 a 17.7 ± 3.3 b 13.7 ± 3.7 b
HGF 268.0 ± 8.4 a,b 44.8 ± 8.6 a 314.0 ± 86.6 b
G-CSF nd nd 52.6 ± 5.9
PDGF-AA 7.9 ± 1.5 a 2.5 ± 4.7 a 6.9 ± 1.7 a
Extracellular matrix proteins (pg/106 cells/day)
Collagen I 76.6 ± 6.0 a 313.2 ± 53.0 b 15.6 ± 0.8 a
Collagen II 2,210.4 ± 911.3 nd nd
Collagen III 12,332.2 ± 0.0 a 17,164.5 ± 689.8 a 38,914.8 ± 477.9 b
Collagen IV 116.5 ± 2.0 a 51.9 ± 4.2 b nd
Elastin 959.3 ± 236.4 a 300.1 ± 6.5 b nd
Fibronectin nd 1.4 ± 1.2 nd
Heparan sulfate 235.6 ± 111.0 a 27.5 ± 233.0 a nd
Laminin 95.5 ± 14.0 a 42.2 ± 15.2 a nd
Aggrecan 2.7 ± 0.1 a 0.2 ± 0.4 a nd
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Table 2 Protein secretion (expressed as mean ± standard deviation) of adipose tissue- (AT-), bone marrow- (BM-) and
Wharton’s Jelly-mesenchymal stromal cells (WJ-MSC) when grown in low glucose media supplemented with 10% fetal
bovine serum (Continued)
Matrix metalloproteinases (pg/106 cells/day)
MMP1 149.6 ± 0.0 a,b 284.2 ± 11.0 a 364.0 ± 36.9 b
MMP3 1,235.1 ± 0.0 a 17,387.1 ± 3,213.2 b 684.2 ± 49.9 a
MMP7 675.6 ± 0.0 a,b 102.9 ± 26.7 a 35.5 ± 15.7 b
MMP8 527.0 ± 152.2 a nd 10.6 ± 157.3 b
MMP13 24,201.6 ± 124.7 a 22.5 ± 0.0 b nd
aFGF: acidic fibroblast growth factor; AT-MSC: adipose tissue-derived MSC; BM-MSC: bone marrow-derived MSC; GCS-F: granulocyte-colony stimulating factor; HGF:
hepatocyte growth facctor; IL: interleukin; IP-10: interferon-gamma induced protein 10; MCP-1: monocyte chemotactic protein 1; MMP: metalloproteinase; nd: not
determined; PDGF-AA: platelet derived growth factor AA; pg: picogram; PLGF: placental growth factor; TGF: transforming growth factor; VEGF: vascular endothelial
growth factor; WJ-MSC: Wharton’s Jelly-derived MSC.
Protein concentration is expressed in pg secreted per million cells and per day. ANOVA and Bonferroni tests (α = 0.5, n = 3) were applied for each quantified factor
in order to determine significant differences between all three MSC. For a specific protein; different letters (superscript letters a, b and c) mean statistically
different expression levels.
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cells/day and 4,466.3 ± 634.6 pg IL-8/106 cells/day,
higher secretion rates when compared to BM- and AT-
MSC.
In the group of anti-inflammatory cytokines, only IL-
1RA was quantified in cell culture supernatants: the
highest secretion rate was 205.3 ± 28.7 pg/106 cells/day
in WJ-MSC, but IL-1RA was undetectable in AT-MSC
supernatants. IL-4, IL-5, IL-10, IL-13 and IFN-α were
not detected in any supernatant.
All the studied angiogenic factors were found in cul-
ture supernatants. BM-MSC secreted the highest con-
centrations of angiogenin, PLGF, aFGF, VEGF-D,
angiopoietin and VEGF. WJ-MSC showed the highest
secretion rates for thrombospondin-2 and endostatin.
PLGF was not detected in WJ-MSC supernatants and
VEGF-D was only detected in BM-MSC cell cultures.
EGF, bFGF, IGF-1, TGF-β3, PDGF-AB and PDGF-BB
were the only growth factors that were not detected in
adipocyte-like cell supernatants. G-CSF was only de-
tected in WJ-MSC, which also secreted the highest
amounts of HGF (314.0 ± 86.6 pg/106 cells/day), as com-
pared to secretion rates of AT-MSC and BM-MSC. BM-
MSC showed the highest secretion rates of PDGF-AA
(7.9 ± 1.5 pg/106 cells/day) and both detected TGF
forms, β1 (4,051.7 ± 0.0 pg/106 cells/day) and β2 (178.1
± 1.1 pg/106 cells/day).
Decorin and perlecan were not detected in any cell
culture supernatant. Only BM-MSC secreted collagen
type II and only AT-MSC secreted fibronectin in detect-
able concentrations. WJ-MSC showed a poor extracellu-
lar matrix production, since several proteins were not
detected in their supernatants (fibronectin, collagen type
II and type IV, heparin sulfate, laminin and aggrecan).
WJ-SC secreted the highest amounts of collagen type III,
AT-MSC secreted the highest amounts of collagen type
I, and BM-MSC collagen type IV. BM-MSC secreted
highest heparan sulfate, laminin, aggrecan and elastin.All the matrix metalloproteinases were detected in
adipocyte-like cell supernatants, except for MMP13 in
WJ-MSC and MMP-8 in AT-MSC. MMP-1 was secreted
in higher concentrations by WJ-MSC, which did not se-
crete MMP-13. We could not detect MMP-8 in AT-
MSC supernatants, but these cells where the best
secreting-cells of MMP-3. BM-MSC were the best se-
creting cells regarding MMP-7, MMP-8 and MMP-13.
Discussion
The present study was performed in order to compare
the MSC derived from bone marrow, adipose tissue and
Wharton’s Jelly along the in vitro differentiation into the
adipocyte-like phenotype, in terms of gene expression
and protein secretion into the culture supernatant. The
major objective was improving the potential protocols
for the “cell-assisted lipotransfer”, obtaining a more effi-
cient and durable gain in volume of the transplanted
tissue. In general terms, we wanted also to check differ-
ences among MSC from three standard sources, often
used in regenerative therapies, when submitted to the
same biological induction of differentiation. Within
these tissues, the MSC populations have different com-
positions and specific functions, which may be partially
maintained during in vitro expansion.
Bone marrow is a traditional source of MSC, in which
the first mesenchymal stem cells giving rise to fibroblas-
toid colonies were described [29]. BM-MSC have
multiple functions, notably the maintenance of the
osteogenic cell pool [30,31] and the provision of the
stroma that sustains hematopoiesis [31]. In the latter
group (BM-MSC differentiating into stromal cells that
gives support to hematopoiesis) are found bone marrow
fat-storing cells, which accumulate lipids in multilocular
droplets, but have several physiological differences as
compared to the typical adipose tissue adipocytes. Bone
marrow also harbors multipotent mesenchymal stem
cells that can be mobilized to the peripheral circulation
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eration in distant organs [33].
Adipose tissue MSC are associated with the vascular
stroma, where they participate in the maintenance of
blood and lymphatic vessels [34]. In the same location,
they can give rise to preadipocytes, already engaged in
adipocyte differentiation and expressing the major mas-
ter genes of this pathway, but without accumulation of
fat [35].
Wharton’s Jelly contains MSC that are not necessarily
associated with vessels and have essentially a mechanical
function [36]. Due to the easy access to this normally
discarded tissue, the broad capacity of proliferation and
the capacity of WJ-MSC to respond to differentiation in-
duction [37,38], these cells are considered to be a rich
source of cells for allogeneic transplantation protocols.
As expected, the present study has shown broad differ-
ences among the MSC behavior during the induction of
the adipocyte-like differentiation. Regarding gene ex-
pression, AT-MSC showed the higher shift in the expres-
sion of adipogenic-related genes (ADIPOQ, PPARG and
CEBPA), when comparing expression after culturing
cells in adipogenic media against baseline expression
(mRNA detected in cells cultured in parallel in control
media). The lipid accumulation was more intense and
rapid in AT-MSC as compared to other MSC. BM-MSC
were able to deposit lipids in droplets (stained with Oil
Red) of similar size as those found in AT-MSC, but the
amount of lipid deposits was lower (as judged per
microscopic visualization; data not shown). In contrast,
WJ-MSC showed a more immature differentiation state
at the end of the induction period (21 days), with few
lipid vacuoles and little lipid accumulation. Similar re-
sults regarding lower adipogenic potential of WJ-MSC
were reported previously by other authors [38,39].
Secretion profile of the adipocyte-like cells isolated from
the three tissues would be expected to be similar, consid-
ering that they were differentiated into the same cell type,
but behaviors were very different among all cells. Chemo-
kines IP-10 and MCP-1 were found in adipocyte-like su-
pernatants, and secretion rates were different among the
three MSC sources. Gerhardt and colleagues described in
the year 2001 MCP-1 secretion by pre-adipocytes and cor-
related it with macrophage recruitment [40]; they demon-
strated that MCP-1 secretion is up-regulated under
inflammatory stimulation (TNF-α) and that secretion is
reduced when pre-adypocytes are fully differentiated
into adipocytes. Therefore, lower MCP-1 secretion by
adipocyte-like cells derived from AT-MSC would indicate
a more advanced differentiation stage. Xu and colleagues
performed in vivo studies in obese mice and hypothesized
that after a certain threshold of obesity, macrophage re-
cruitment (through MCP-1 secretion) is improved, result-
ing in a feedback loop where insulin signaling is impaired,leading to adipocyte lipolysis and necrosis [41]. Human
adipocyte secretion of IP-10 was also confirmed and was
positively correlated with body mass index [42].
IL-6 and IL-7 secretion by adipocytes was confirmed
in 1997 and 2007, respectively, and plasmatic concentra-
tions of both cytokines were positively correlated with
obesity [43,44] Regarding IL-8, results are not conclu-
sive: Okada and coworkers reported that IL-8 secretion
was augmented after BM-MSC adipogenesis [45], similar
to what we obtained, if we compare secretion of
adipocyte-like cells derived from BM-MSC and basal se-
cretion (47.8 ± 11.7 versus 628.3 ± 8.0 pg/106 cells/day;
24). On the other side, Fain reported in 2006 that non-
fat cells of adipose tissue secrete higher concentrations
of IL-8, when compared with adipocytes [46]. These re-
sults are in agreement with what we are reporting here:
undifferentiated AT-MSC showed a higher IL-8 secre-
tion rate than adipocyte-like cells derived from these
cells [24]. When looking at IL-12, Blaber and coworkers
found that IL-12 secretion was higher in AT-MSC than
in adipocytes, results that agree with what we found for
AT- and WJ-MSC, but not for BM-MSC [46]. As we re-
ported here, IL-5 was not detected in supernatants of
human adipocytes [47].
While we did not detected IFN-γ, IL1β, IL17, TNFα,
IL4, IL13, IL10, MIP1α, bFGF, GM-CSF and IL2 in
adipocyte-like cell supernatant, Blaber and colleagues
also reported low concentrations of these cytokines in
adipocyte supernatants, suggesting a difference in secre-
tome composition when comparing mature adipocytes
with adipocyte-like cells obtained by differentiation in-
duction of MSC [47].
All angiogenic factors were expressed by adipocyte-
like cells and by the MSC as well [24]. Already during
embyogenesis, angiogenesis and adipogenesis are
strongly related and it was previously demonstrated that
AT-MSC, pre-adipocytes and adipocytes secrete a variety
of angiongenic factors (reviewed in [48]). Pro-
inflammatory cytokines are also involved in angiogen-
esis, since they attract cells that also are able to secrete
pro-angiogenic factors. Angiogenesis is highly desirable
during fat transplantation, since new vasculature would
allow tissue survival and less reabsortion. Therefore,
adipocyte-like cells derived from BM-MSC would
be a good supplement for adipose tissue during
transplantation.
Metalloproteinases (MMPs) are essential during angio-
genesis and consequently during adipose tissue develop-
ment. Adipose tissue secretes several MMPs, like MMP-3
and −13, and downregulation was observed for other
MMPs, like MMP-7 (reviewed in [48]). Neither WJ-
MSC nor adipocyte-like cells from WJ-MSC secreted
MMp-13 in detectable concentrations; the same for
MMP-8 in AT-MSC and adipocytes differentiated from
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tion after differentiation, again indicating suitability for
fat transplantation supplementation. MMP-3 degrades
several types of extracellular matrix proteins, like colla-
gen types II, III, IV, IX, and X, proteoglycans, fibronec-
tin, laminin, and elastin and can also activate other
MMPs, such as MMP-1, MMP-7, and MMP-9.
Growth factors found in adipocyte-like cells were G-
CSF, HGF, PDGF-AA and TGF-β1 and β2. Rahimi and
colleagues reported in 1998 that pre-adipocytes and adi-
pocytes secreted both TGF-β1 and β2 and that these
growth factors negatively affected adipocyte differenti-
ation [49]. Our results showed an increased TGF secre-
tion rate for all MSC differentiating into adipocyte-like
cells, except for TGF-β2 in adipocyte-like cells derived
from WJ-MSC. No information regarding PDGF-AA se-
cretion by adipocytes was found, but since this molecule
is a potent mitogen for MSC, its secretion is considered
positive for fat transplantation. Results reported before
by our group showed that non-induced BM-, AT- and
WJ-MSC secreted PDGF-BB. In the present study, after
adipogenic differentiation PDGF-BB was not detected in
any supernatant, indicating a downregulation when cells
enter the adipogenic differentiation pathway [24].
Collagen type IV is the most abundant collagen type in
adipose tissue and its absence had been linked with obes-
ity [50]. Considering our results, WJ-MSC would not be
appropriate cells for fat transplantation, since neither the
undifferentiated cells nor the adipocyte-like cells derived
from them secreted detectable concentrations of collagen
type IV. On the other side, BM-MSC did not secreted de-
tectable concentrations of collagen type IV while undiffer-
entiated but adipogenic media stimulated its secretion at a
rate of 116.5 ± 2.0 pg/106 cells/day. Nakajima and co-
workers reported that laminin and fibronectin are also im-
portant components of adipose tissue extracellular matrix,
while collagen type II was found in an extremely low
amount [51]. Fibronectin was not detected in any MSC
supernatant [24] and after adipogenic differentiation, only
adipocyte-like cells derived from AT-MSC secreted it in
detectable concentrations. Laminin was secreted by BM-
and AT-MSC in both, differentiated and undifferentiated
states, but no laminin was detected in WJ-MSC superna-
tants. Collagen type II was only quantified in adipocytes
derived from BM-MSC. Another important result we
obtained here is that adipocyte-like cells derived from WJ-
MSC were poor producers of extracellular matrix compo-
nents and this correlated with results reported before by
our group where undifferentiated WJ-MSC secretion was
quantified [24].
Conclusions
AT-MSC, BM-MSC and WJ-MSC were successfully dif-
ferentiated into adipogenic-like cells under appropriatestimulation by the culture media. Considering the be-
havior described in vitro for all three adipocyte-like cells
obtained in the present work, AT- and BM-MSC would




All donors signed an informed consent before tissue do-
nation. Ethics Research Committee of the Pro-Cardiaco
Hospital (Rio de Janeiro, Brazil) reviewed and approved
isolation and use in research of adipose tissue-derived
mesenchymal stem cells (AT-MSC; CEP: 55219/12),
Wharton’s Jelly-derived mesenchymal stem cells (WJ-
MSC; CEP: 336/10), and bone marrow-derived mesen-
chymal stem cells (BM-MSC; CEP: 473/12).
Cell preparation and adipogenic differentiation in vitro
MSC were isolated as described previously [21]. MSC
identity was confirmed by following the guidelines estab-
lished by the Mesenchymal and Tissue Stem Cell Com-
mittee of the International Society for Cellular Therapy:
MSC must adhere to plastic under standard conditions,
express surface molecules and differentiate into osteo-
blasts, adipocytes and chondroblasts [22]. Cells were ex-
panded until passage number 3, by detaching the cells
using trypsin, determining the concentration by manual
counting and diluting the cells to 5 × 105 cells/mL; pas-
sages were performed every four days. A pool for each
MSC was prepared by mixing MSC derived from four
different donors so donor-dependent variability was de-
creased. Three replicates were performed for each assay
using the same pool of cells.
Cell pools were seeded into 24-well plates (2 mL/well)
at 25,000 cells/mL. Differentiation medium was replaced
twice a week. It consisted of low glucose DMEM
(BR30002-05, LGC, Cotia, São Paulo, Brazil) supple-
mented with 10% fetal bovine serum (FBS, #10-BIO-500
LGC, Cotia, São Paulo, Brazil), 1 μM dexamethasone
(D4902, Sigma, St. Louis, Missouri, USA), 0.5 mM 3-
isobutyl-1-methylxanthine (I7018, Sigma, St. Louis,
Missouri, USA), 10 μM human insulin (Humulin-N, Eli
Lilly, Indianapolis, Indiana, USA), 0.2 mM indomethacin
(I7378, Sigma, St. Louis, Missouri, USA) and a penicil-
lin/streptomycin solution (BR30110-01, LGC, Cotia, São
Paulo, Brazil) at 100 U/mL and 100 μg/mL, respectively.
After 3 weeks, cells were incubated with 0.5% Oil Red O
solution (O0625, Sigma, St. Louis, Missouri, USA) in
order to stain intracellular accumulated lipids.
RNA extraction and qPCR
RNeasy Plus Mini kit (#74134, QIAGEN, Germantown,
Maryland, USA) was used for purifying total RNA from
freshly isolated cells (t = 0) or cells submitted to culture
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10 or 21 days). RNA concentration was determined
using a Nanodrop 2000 UV–vis spectrophotometer
(Thermo Scientific, Waltham, Massachusetts, USA).
Purified RNA was retro-transcribed using a SuperScript
VILO Mastermix (#11755250, Invitrogen, Carlsbad,
California USA), according to manufacturer’s instruc-
tions. qPCR reactions were performed in an Applied
Biosystems 7500 Fast Real Time PCR System using
TaqMan Gene Expression Mastermix (#4369510, Ap-
plied Biosystems, Foster City, California, USA), accord-
ing to manufacturer’s instructions. Pre-designed TaqMan
Gene Expression assays (#4331182, Applied Biosystems,
Foster City, California, USA) were used to quantify the
relative expression levels of pluripotent and adipogenic
genes. Assay identification numbers used in the present
work are: Hs02800695_m1 for the analysis of HPRT1 ex-
pression (reference gene), Hs03043885_g1 for the ana-
lysis of RPL13A expression, Hs01053049_s1 for the
analysis of SOX2 expression, Hs00999634_gH for the
analysis of POU5F1 expression, Hs00972656_m1 for the
analysis of TERT expression, Hs01115513_m1 for the
analysis of PPARG expression, Hs00605917_m1 for the
analysis of ADIPOQ expression and Hs00269972_s1 for
the analysis of CEPBA expression. Data was analyzed
using the 2^(−delta delta Ct) method as previously de-
scribed by Livak and colleagues [23]; relative gene ex-
pression from differentiated cells is calculated relative to
the expression of the same gene in non-differentiated
cells (growth in parallel during 21 days under control
media).
Cytokine, growth factor and extracellular matrix
quantification
We used commercial Luminex and ELISA kits for quan-
tifying cell supernatant concentration of 49 different
cytokines, growth factors and extracellular matrix-
related proteins. Human Cytokine 30-plex Assay
(Invitrogen, Carlsbad, California USA) was used for the
quantification of chemokines, pro-and anti-inflammatory
cytokines and growth factors (GM-CSF, G-CSF, IL-1β,
IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10,
IL-12p40/p70, IL-13, IL-15, IL-17, TNF-α, IFN-α,
IFN-γ, eotaxin, IP-10, MCP-1, MIG, MIP-1α, MIP-1β,
RANTES, EGF, bFGF, HGF, VEGF). TGF-β1, TGF-β2
and TGF-β3 were quantified using the Fluorokine MAP
TGF-β Multiplex Kit (R&D, Minneapolis, Minnesota,
USA). Human Angiogenesis Fluorokine Multi Analyte
Profiling Kit (R&D, Minneapolis, Minnesota, USA) was
customized for the quantification of angiogenic growth
factors (VEGF-D, endostatin, aFGF, thrombospondin-2,
angiopoietin-1, angiogenin, PDGF-AA, PDGF-BB and
PlGF). Matrix metalloproteinases (MMP-1, −3, −7, −8
and −13) were quantified using the Fluorokine MAPHuman MMP kit (R&D, Minneapolis, Minnesota, USA)
and Milliplex MAP Human IGF-1 Single Plex Kit
(Millipore, Billerica, Massachusetts, USA) was used for
IGF-1 quantification. PDGF-AB was quantified using an
ELISA kit Quantikine hPDGF-AB ELISA (R&D, Minneapolis,
Minnesota, USA). Extracellular matrix components heparan
sulphate, aggrecan, decorin, elastin, laminin, perlecan,
fibronectin and collagens type I, II, III and IV were quanti-
fied in cell culture supernatants using commercial ELISA
kits (E0623h, E91908Hu, E92127Hu, E91337Hu,
E90082Hu, E82748Hu, E90037Hu, E90571Hu, E90572Hu,
E90176Hu and E90180Hu, respectively; USCN, Wuhan,
Hubei, China). Procedures were performed according to
manufacturer’s instructions in all cases.
We analyzed cell supernatants obtained from the last
differentiation culture media replacement, just before
staining for lipid accumulation. Since cell concentration
was different for the three cell types at the end of the adi-
pogenic differentiation, protein concentrations were nor-
malized by final cell concentration (determined by manual
counting using Trypan Blue after detaching the cells using
trypsin) and incubation time since last culture media re-
placement, expressing the results in pg/106 cells/day (con-
sidering final cell concentration, since protein content
refers to the last 3 days of the culture). Results were
expressed as mean ± standard deviation for 3 replicates.
Statistical analysis
Statistical significance was assessed by one-way non-
parametric ANOVA followed by Bonferroni post-hoc
test to compare all pairs of data. P-values < 0.05 were
considered statistically significant. Statistical analysis was
performed using the Prism 5.00 Software (GraphPad
Software Inc., San Diego, California, USA).
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